IL-5-producing CD4 + T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer

Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses require tightly regulated crosstalk between innate and adaptive immune cells. Here, we combine...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancer cell Ročník 41; číslo 1; s. 106
Hlavní autori: Blomberg, Olga S, Spagnuolo, Lorenzo, Garner, Hannah, Voorwerk, Leonie, Isaeva, Olga I, van Dyk, Ewald, Bakker, Noor, Chalabi, Myriam, Klaver, Chris, Duijst, Maxime, Kersten, Kelly, Brüggemann, Marieke, Pastoors, Dorien, Hau, Cheei-Sing, Vrijland, Kim, Raeven, Elisabeth A M, Kaldenbach, Daphne, Kos, Kevin, Afonina, Inna S, Kaptein, Paulien, Hoes, Louisa, Theelen, Willemijn S M E, Baas, Paul, Voest, Emile E, Beyaert, Rudi, Thommen, Daniela S, Wessels, Lodewyk F A, de Visser, Karin E, Kok, Marleen
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 09.01.2023
Predmet:
Animals
Antigen Presentation
CD4-Positive T-Lymphocytes - pathology
CD8-Positive T-Lymphocytes
Eosinophils - pathology
Immune Checkpoint Inhibitors - therapeutic use
Interleukin-33
Interleukin-5 - therapeutic use
Mice
Neoplasms - drug therapy
myeloid cells
CD4(+) T cells
IL-5
breast cancer
eosinophils
IL-33
immune checkpoint blockade
ISSN:1878-3686, 1878-3686
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses require tightly regulated crosstalk between innate and adaptive immune cells. Here, we combine unbiased analysis of blood and tumors from metastatic breast cancer patients treated with ICB with mechanistic studies in mouse models of breast cancer. We observe an increase in systemic and intratumoral eosinophils in patients and mice responding to ICB treatment. Mechanistically, ICB increased IL-5 production by CD4 T cells, stimulating elevated eosinophil production from the bone marrow, leading to systemic eosinophil expansion. Additional induction of IL-33 by ICB-cisplatin combination or recombinant IL-33 promotes intratumoral eosinophil infiltration and eosinophil-dependent CD8 T cell activation to enhance ICB response. This work demonstrates the critical role of eosinophils in ICB response and provides proof-of-principle for eosinophil engagement to enhance ICB efficacy.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1878-3686
1878-3686
DOI:10.1016/j.ccell.2022.11.014